Compare Expeditors International of Wshngtn Inc (EXPD) vs Novavax Inc (NVAX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Expeditors International of Wshngtn Inc vs Novavax Inc — how do they compare? Expeditors International of Wshngtn Inc trades at $193.24 (market cap $25.18B), while Novavax Inc trades at $12.75 (market cap $1.82B). The key difference: Expeditors International of Wshngtn Inc is far larger — about 13.8× Novavax Inc's market cap, and Expeditors International of Wshngtn Inc pays a 0.84% dividend while Novavax Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Expeditors International of Wshngtn Inc for 43 Days and Novavax Inc for 59 Days on average.
| EXPD | NVAX | |
|---|---|---|
Market Cap | $25.18B | $1.82B |
Volume | 1,003,557 | 6,198,505 |
Sector | Industrials | Health |
52-Week High | $194.12 | $12.56 |
52-Week Low | $113.13 | $6.22 |
Typical Hold Time | 43 Days | 59 Days |
Enterprise Value | $24.72B | $1.39B |
Dividend Yield | 0.84% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
EXPD trades at $193.71, up 1.5% with a bullish technical signal supported by moving averages. The company demonstrates strong profitability with 7.63% net income margin and exceptional ROE of 42.6%, though revenue growth remains modest. Recent earnings beats and positive analyst coverage highlight operational strength amid resilient airfreight demand and efficiency initiatives.
While valuation multiples appear elevated (P/E 28.2), consistent earnings outperformance and institutional interest support upside potential. Key risks include freight market volatility and competitive pressures. The consensus price target of $179.43 suggests modest downside from current levels, requiring careful risk-reward assessment.
Novavax (NVAX) trades at $11.01, down 1.87% on the day, with a bullish technical signal from moving averages and strong analyst support (73.9% buy ratings). The company reported revenue of $1.12B in 2025 with a net income of $440.3M, marking a significant turnaround from prior losses, though 2026 projections show a return to negative net income. Recent news highlights regulatory approvals for its COVID-19 vaccine and strategic pivots toward its Matrix-M adjuvant platform through partnerships.
The outlook is mixed: strong valuation ratios (P/E of 3.14, EV/EBITDA of 1.72) and recent earnings beats suggest undervaluation, but persistent cash burn and negative equity pose risks. Investment opportunity lies in partnership-driven growth, while risks include execution challenges and reliance on vaccine demand. Wall Street sentiment remains optimistic despite fundamental volatility.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Expeditors International of Wshngtn Inc
Expeditors International of Washington is a non-asset-based third-party logistics provider, mainly focused on international freight forwarding. It employs sophisticated IT systems and contracts with airlines and ocean carriers to move customers' freight across the globe. The firm operates more than 200 full-service office locations worldwide, in addition to numerous satellite locations. In 2021, Expeditors derived 38% of consolidated net revenue from airfreight, 27% from ocean freight, and 35% from customs brokerage and other services.
Read more on EXPD →About Novavax Inc
Novavax, Inc. is a clinical stage biotechnology company. The Company creates novel vaccines to address a broad range of infectious diseases worldwide using proprietary virus-like particle (VLP) technology.
Read more on NVAX →
